June 23 (Reuters) - Compass Pathways' (CMPS.O), opens new tab psilocybin-based depression therapy reduced the severity of symptoms in a closely watched study, but shares of the biotech firm plunged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback